Leukemia Treatment Options: Comprehensive Overview by Modality

Leukemia treatment is highly individualized based on type (ALL, AML, CLL, CML), subtype/genetics, patient age/fitness, and disease status. A multidisciplinary team (hematology/oncology, transplant, pathology, supportive care) designs the plan.

Core Treatment Modalities

1. Chemotherapy: Cytotoxic drugs (anthracyclines, cytarabine, vincristine, corticosteroids, alkylators). Routes: IV, oral, intrathecal (CNS prophylaxis). Backbone of acute leukemia induction/consolidation.
2. Targeted Therapy:
   • TKIs (imatinib, dasatinib, nilotinib, bosutinib, ponatinib) → CML, Ph+ ALL.
   • FLT3 inhibitors (midostaurin, gilteritinib) → FLT3-mutated AML.
   • BCL-2 inhibitor (venetoclax) + azacitidine → older/unfit AML, CLL.
   • BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) → CLL, mantle cell.
   • PI3Kδ inhibitors (idelalisib, duvelisib) → relapsed CLL/FL.
3. Immunotherapy:
   • CAR T-cell therapy (tisagenlecleucel, brexucabtagene) → R/R B-ALL, large B-cell lymphoma.
   • Bispecific antibodies (blinatumomab → CD19/CD3; teclistamab → BCMA/CD3).
   • Checkpoint inhibitors (limited role; Hodgkin lymphoma).
   • Monoclonal antibodies (rituximab, obinutuzumab → CD20; inotuzumab → CD22).
4. Radiation Therapy: CNS prophylaxis (ALL), sanctuary sites, splenic irradiation, pre-transplant TBI.
5. Hematopoietic Stem Cell Transplant (HSCT):
   • Allogeneic: Curative for high-risk AML, ALL, CML blast phase; GVHD risk.
   • Autologous: Consolidation for myeloma, lymphoma; rare in acute leukemia.
6. Supportive Care: Transfusions, growth factors (G-CSF), antimicrobial prophylaxis, TLS prevention, palliative integration.
7. Clinical Trials: Access to novel agents (menin inhibitors, CD70 ADC, universal CAR-T, etc.). Strongly encouraged at all phases.

Decision Factors

• Molecular genetics (NGS panel) — defines eligibility for targeted agents.
• Comorbidities / HCT-CI (transplant fitness).
• Patient goals & values.

Treatment landscapes evolve rapidly. NCCN/ELN guidelines and specialist consultation are essential for current standards.